Optimer completes fidaxomicin NDA submission

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) completed submission of a rolling NDA to FDA for fidaxomicin to treat Clostridium difficile infection (CDI) and to prevent recurrences of CDI. The company r...